Dr. Ted Berei and CardioScripts co-host, Dr. Tracy Macaulay, discuss the EMPEROR-Reduced trial.
0:00-0:28: Introduction
0:29-1:05: Introduction of Dr. Ted Berei
1:06-3:40: EMPEROR-Reduced Overview
3:41-5:08: Overall Thoughts
5:09 -11:18: Secondary Endpoints
11:19-19:04: Considerations for Initiation of SGLT2 Inhibitors
19:05-21:21: Final Thoughts
21:22-22:02: Closing
References:
- McMurray, John JV, et al. “Dapagliflozin in patients with heart failure and reduced ejection fraction.” New England Journal of Medicine 381.21 (2019): 1995-2008.
- Packer, Milton, et al. “Cardiovascular and renal outcomes with empagliflozin in heart failure.” New England Journal of Medicine 383.15 (2020): 1413-1424.
- Vardeny, Orly, and Muthiah Vaduganathan. “Practical guide to prescribing sodium-glucose cotransporter 2 inhibitors for cardiologists.” JACC: Heart Failure 7.2 (2019): 169-172.
- Das, Sandeep R., et al. “2020 expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes: a report of the American College of Cardiology solution set oversight committee.” Journal of the American College of Cardiology 76.9 (2020): 1117-1145.
CardioScripts 